Cargando…

Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects

BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis without precipitating factors in non-type 1 diabetic patients; after management, some are withdrawn from exogenous insulin, although determining factors remain unclear. METHODS: Twenty KPDM patients and twelve type 1 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yan, Gupta, Priyanka, Lapointe, Marc, Yotsapon, Thewjitcharoen, Sarat, Sunthornyothin, Cianflone, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183552/
https://www.ncbi.nlm.nih.gov/pubmed/25275325
http://dx.doi.org/10.1371/journal.pone.0109237
_version_ 1782337711651160064
author Liu, Yan
Gupta, Priyanka
Lapointe, Marc
Yotsapon, Thewjitcharoen
Sarat, Sunthornyothin
Cianflone, Katherine
author_facet Liu, Yan
Gupta, Priyanka
Lapointe, Marc
Yotsapon, Thewjitcharoen
Sarat, Sunthornyothin
Cianflone, Katherine
author_sort Liu, Yan
collection PubMed
description BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis without precipitating factors in non-type 1 diabetic patients; after management, some are withdrawn from exogenous insulin, although determining factors remain unclear. METHODS: Twenty KPDM patients and twelve type 1 diabetic patients (T1DM), evaluated at baseline, 12 and 24 months with/without insulin maintenance underwent a standardized mixed-meal tolerance test (MMTT) for 2 h. RESULTS: At baseline, triglyceride and C3 were higher during MMTT in KPDM vs. T1DM (p<0.0001) with no differences in non-esterified fatty acids (NEFA) while Acylation Stimulating Protein (ASP) tended to be higher. Within 12 months, 11 KPDM were withdrawn from insulin treatment (KPDM-ins), while 9 were maintained (KPDM+ins). NEFA was lower in KPDM-ins vs. KPDM+ins at baseline (p = 0.0006), 12 months (p<0.0001) and 24 months (p<0.0001) during MMTT. NEFA in KPDM-ins decreased over 30–120 minutes (p<0.05), but not in KPDM+ins. Overall, C3 was higher in KPDM-ins vs KPDM+ins at 12 months (p = 0.0081) and 24 months (p = 0.0019), while ASP was lower at baseline (p = 0.0024) and 12 months (p = 0.0281), with a decrease in ASP/C3 ratio. CONCLUSIONS: Notwithstanding greater adiposity in KPDM-ins, greater NEFA decreases and lower ASP levels during MMTT suggest better insulin and ASP sensitivity in these patients.
format Online
Article
Text
id pubmed-4183552
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41835522014-10-07 Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects Liu, Yan Gupta, Priyanka Lapointe, Marc Yotsapon, Thewjitcharoen Sarat, Sunthornyothin Cianflone, Katherine PLoS One Research Article BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis without precipitating factors in non-type 1 diabetic patients; after management, some are withdrawn from exogenous insulin, although determining factors remain unclear. METHODS: Twenty KPDM patients and twelve type 1 diabetic patients (T1DM), evaluated at baseline, 12 and 24 months with/without insulin maintenance underwent a standardized mixed-meal tolerance test (MMTT) for 2 h. RESULTS: At baseline, triglyceride and C3 were higher during MMTT in KPDM vs. T1DM (p<0.0001) with no differences in non-esterified fatty acids (NEFA) while Acylation Stimulating Protein (ASP) tended to be higher. Within 12 months, 11 KPDM were withdrawn from insulin treatment (KPDM-ins), while 9 were maintained (KPDM+ins). NEFA was lower in KPDM-ins vs. KPDM+ins at baseline (p = 0.0006), 12 months (p<0.0001) and 24 months (p<0.0001) during MMTT. NEFA in KPDM-ins decreased over 30–120 minutes (p<0.05), but not in KPDM+ins. Overall, C3 was higher in KPDM-ins vs KPDM+ins at 12 months (p = 0.0081) and 24 months (p = 0.0019), while ASP was lower at baseline (p = 0.0024) and 12 months (p = 0.0281), with a decrease in ASP/C3 ratio. CONCLUSIONS: Notwithstanding greater adiposity in KPDM-ins, greater NEFA decreases and lower ASP levels during MMTT suggest better insulin and ASP sensitivity in these patients. Public Library of Science 2014-10-02 /pmc/articles/PMC4183552/ /pubmed/25275325 http://dx.doi.org/10.1371/journal.pone.0109237 Text en © 2014 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Liu, Yan
Gupta, Priyanka
Lapointe, Marc
Yotsapon, Thewjitcharoen
Sarat, Sunthornyothin
Cianflone, Katherine
Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
title Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
title_full Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
title_fullStr Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
title_full_unstemmed Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
title_short Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
title_sort acylation stimulating protein, complement c3 and lipid metabolism in ketosis-prone diabetic subjects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183552/
https://www.ncbi.nlm.nih.gov/pubmed/25275325
http://dx.doi.org/10.1371/journal.pone.0109237
work_keys_str_mv AT liuyan acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects
AT guptapriyanka acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects
AT lapointemarc acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects
AT yotsaponthewjitcharoen acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects
AT saratsunthornyothin acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects
AT cianflonekatherine acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects